Drug name review: Science takes the spotlight in 2022
Science was the name of the game in pharma drugs last year — literally. FDA-approved drug names in 2022 leaned heavily on science associations, according to experts. While that’s not unusual, in a year of fewer approvals than any in the past six years, the overall naming conventions more often recalled familiar strategy than breakout surprise.
Why? One of the leading reasons is that it’s just harder to come up with unique, attribute-related names. In part, that’s because they’ve already been trademarked and are off-market, while the FDA is more discerning about the overt use of product attributes or potential benefits in brand names.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.